(Q53899679)

English

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Koen van Besien

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Fernando Cabanillas

16

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

1

object named as

Popat U

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

3

object named as

Saliba RM

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Richard E Champlin

18

object named as

Champlin RE

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

10

object named as

Giralt S

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

7

object named as

Khouri IF

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

author name string

Anderlini P

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Przepiorka D

6

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Gajewski J

8

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Claxton D

9

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Rodriguez M

11

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Romaguera J

12

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Hagemeister F

13

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Ha C

14

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Cox J

15

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Andersson BS

17

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

33

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

10

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

1015-1023

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704483

0 references

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

The Analysis of Failure Times in the Presence of Competing Risks

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Should high risk patients with Hodgkin's disease be singled out for heavier therapeutic regimens while low risk patients are spared such therapies?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Chemotherapy and Survival in Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Hodgkin's disease: Combination chemotherapy for relapse following radical radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage radiotherapy in recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year nodular sclerosis Hodgkin's disease and second malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704483

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15048145

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53899679&oldid=1810054711"